Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2016

View Archived Issues

Novogen presents TMP3 inhibitors

Tolero initiates first-in-human study of oral TP-0903 in patients with advanced solid tumors

MacroGenics and Synthon Biopharmaceuticals sign antibody-drug conjugate agreement

microRNA-103-1 shows promise as a biomarker of ischemic brain damage

Novel oligomerspecific scFv antibody shows promise in several animal models of amyloidosis

Salmonella meningitis is associated with monocyte infiltration in mouse models

Novel HIV-1-specific bNAb can achieves near pan-neutralization of HIV-1

Chinese scientists patent FGFR inhibitors

Idenix Pharmaceuticals and Southern Research Institute disclose nucleoside derivatives

FDA approves MACI to repair knee cartilage defects

Bristol-Myers Squibb selects CTLA-4 Probody candidate from collaboration with CytomX

Sage begins phase II trials of SAGE-217 in Parkinson's disease and essential tremor

European Commission approves Ferring's Rekovelle

Topline data from phase III PATENCY-1 study of investigational vonapanitase in patients with CKD

Wi2 and Orion announce strategic collaboration in oncology

Centrexion Therapeutics reports topline data from phase IIb study of CNTX-4975

AcelRx Pharmaceuticals submits NDA to FDA for ARX-04

Genticel ends HPV therapeutics program based on phase II trial results

FDA accepts Dimension Therapeutics' IND for DTX-301

BioDelivery Sciences discontinues clonidine topical gel

Topline results from phase III trial of istradefylline in Parkinson's disease

Johnson & Johnson ends transaction discussions with Actelion

First clinical data for DCC-2618

Data reported from phase I study of first-in-class antisense oligonucleotide targeting AR

Phase I study of sEphB4-HSA in advanced solid tumors

First phase I data for of ravoxertinib in advanced solid tumors

Ab Initio Biotherapeutics and Pfizer enter GPCR collaboration

Spotlight Innovation obtains rights to compounds for Zika virus infection

First-in-human data for AstraZeneca's ATR inhibitor AZD-6738

EMA grants UGT1A1 gene therapy orphan designation for Crigler-Najjar syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...